| Open Document File Size: 4,36 MBShare Result on Facebook
Company ITT / / Country United States / / Event FDA Phase / / Facility TRAIL Making Test-B / Laboratory Findings / / IndustryTerm treatment of hyponatremia associated with syndrome / Chemical structure / / MedicalCondition congestive heart failure / No osmotic demyelination syndrome / SIADH use / cancer / hypervolemic hyponatremia / hyponatremia population / headache / coma / severe lethargy / osmotic demyelination syndrome / seizure / Hyponatremia / fatigue / heart failure / hyponatremia and congestive heart failure / hyponatremia trials / hyponatremia requiring / SIADH / euvolemic hyponatremia / depression / syndrome / hyponatremia classifications / / Organization Food and Drug Administration / Review Division / FDA / Advisory Committee / / Person Nancy N. Xu / / Position Investigator / Major / / Product Lixivaptan Proposed Indication / V1a / / PublishedMedium the Clinical Pharmacology Clinical Review / the Clinical Pharmacology Review / Baseline / / Technology Pharmacokinetics / Pharmacodynamics / /
SocialTag |
FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012